Journal of Neuro-Oncology

, Volume 106, Issue 1, pp 147–153 | Cite as

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

  • Mark R. Gilbert
  • John Kuhn
  • Kathleen R. Lamborn
  • Frank Lieberman
  • Patrick Y. Wen
  • Minesh Mehta
  • Timothy Cloughesy
  • Andrew B. Lassman
  • Lisa M. DeAngelis
  • Susan Chang
  • Michael Prados
Clinical Study – Patient Study


Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the αvβ3 and αvβ5 integrins. Preclinical studies demonstrate antiangiogenic activity and anti-invasive activity in a number of glioma models. This study was designed to evaluate the efficacy and tumor delivery of cilengitide in patients with recurrent glioblastoma. Patients with recurrent glioblastoma who require a surgical resection for optimal clinical care received 3 intravenous doses of cilengitide at either 500 or 2000 mg (day -8, -4, -1) prior to undergoing tumor resection with corresponding blood samples for plasma to tumor comparisons. After recovery from surgery, patients were treated with cilengitide (2000 mg i.v. twice weekly, maximum of 2 years of treatment). The study accrued 30 patients with recurrent glioblastoma, 26 were evaluable for efficacy. The 6-month progression free survival rate was 12%. Cilengitide was detected in all tumor specimens with higher levels in the group receiving 2000 mg dosing while corresponding plasma concentrations were low, often below the lower limit of detection. These results confirm drug delivery and possibly retention in tumor. This study provides evidence that with established dosing, cilengitide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent glioblastoma is modest. However, these results demonstrating drug delivery to tumor do support continued investigation of this agent as preliminary results from recent studies combining cilengitide with cytotoxic therapies are promising.


Glioblastoma Pharmacokinetics Tumor pharmacokinetics Integrins 



The Cilengitide was generously provided by Merck KgaA and the National Cancer Institute, NIH. This study was sponsored by NIH Grant U01 CA-062412.

Conflict of interest

Mark R. Gilbert, MD: Research support from Genentech, Advisory Affiliations with Merck, Genentech.

John Kuhn, Pharm D., Kathleen R. Lamborn, PhD, Patrick Y. Wen, MD, Timothy Cloughesy, MD, Lisa M. DeAngelis, MD, Susan Chang, MD, and Michael Prados, MD: None.

Frank Lieberman, MD: Advisory affiliations with Roche/Genentech. Paid consulting with Roche/Genentech and EMD Merck.

Minesh Mehta, MD: Consultant to Adnexus, Bayer, Genenteh, Merck, Schering Plough, YM BioSciences and Tomotherapy; on the Board of Directors of Pharmacyclics, an advisor to Colby and Stemina, and is on the DSMB for Apogenix. He holds stock options in Pharmacyclics and Tomotherapy.

Andrew B. Lassman, MD: Research support from Schering Plough, Sigma Tau, Genentech, Keryx, Astra Zeneca, Exelixis. Advisory affiliations with Bristol-Myers Squibb, Campus Bio, Cephalon, Eisai, Enzon, Genentech, Imclone, Schering-Plough, Merck. Paid consulting with Schering Plough, Merck.


  1. 1.
    Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncology 10(2):162–170PubMedCrossRefGoogle Scholar
  2. 2.
    de Groot JF, Gilbert MR (2007) New molecular targets in malignant gliomas. Curr Opin Neurol 20(6):712–718PubMedCrossRefGoogle Scholar
  3. 3.
    Folkman J (2006) Angiogenesis. Annu Rev Med 57(1):1–18PubMedCrossRefGoogle Scholar
  4. 4.
    Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149(1):293–305PubMedGoogle Scholar
  5. 5.
    Tonn JC, Wunderlich S, Kerkau S, Klein CE, Roosen K (1998) Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 18(4A):2599–2605PubMedGoogle Scholar
  6. 6.
    Eliceiri BP, Cheresh DA (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103(9):1227–1230PubMedCrossRefGoogle Scholar
  7. 7.
    Byzova TV, Rabbani R, D’Souza SE, Plow EF (1998) Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost 80(5):726–734PubMedGoogle Scholar
  8. 8.
    Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270(5241):1500–1502PubMedCrossRefGoogle Scholar
  9. 9.
    Gladson CL (1996) Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55(11):1143–1149PubMedCrossRefGoogle Scholar
  10. 10.
    Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49(2):380–389 discussion 390PubMedGoogle Scholar
  11. 11.
    Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY (2000) Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 46(2):135–144PubMedCrossRefGoogle Scholar
  12. 12.
    MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48(1):151–157PubMedGoogle Scholar
  13. 13.
    Nabors L, Rosenfeld S, Mikkelsen T et al (2004) NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Neuro-oncology 6(4):379Google Scholar
  14. 14.
    Reardon D, Fink K, Nabors B, Cloughesy T, Plotkin S, Schiff D, Raizer J, Krueger S, Picard M, Mikkelsen T (2007) Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. J Clin Oncol 25(Suppl. 18):2002Google Scholar
  15. 15.
    Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572PubMedGoogle Scholar
  16. 16.
    Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15):1200–1206PubMedCrossRefGoogle Scholar
  17. 17.
    Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651–1657PubMedCrossRefGoogle Scholar
  18. 18.
    Stupp R, Goldbrunner B, Neyns B, Schlegel U, Clement P, Grabenbauer G, Hegi ME, Nippgen M, Picard M, Weller M (2007) Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 25(Suppl. 18):2000Google Scholar
  19. 19.
    Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39(7):917–926PubMedCrossRefGoogle Scholar
  20. 20.
    Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610–5617PubMedCrossRefGoogle Scholar
  21. 21.
    MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26(6):919–924PubMedCrossRefGoogle Scholar
  22. 22.
    Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncology 11(6):747–756PubMedCrossRefGoogle Scholar
  23. 23.
    Nabors LB, Mikkelsen T, Batchelor TT, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman SA (2009) NABTT 0306: a randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 27(15s):abstr. 2001Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Mark R. Gilbert
    • 1
  • John Kuhn
    • 2
  • Kathleen R. Lamborn
    • 3
  • Frank Lieberman
    • 4
  • Patrick Y. Wen
    • 5
  • Minesh Mehta
    • 6
  • Timothy Cloughesy
    • 7
  • Andrew B. Lassman
    • 8
  • Lisa M. DeAngelis
    • 8
  • Susan Chang
    • 3
  • Michael Prados
    • 3
  1. 1.Department of Neuro-oncologyM. D. Anderson Cancer Center, The University of TexasHoustonUSA
  2. 2.The University of Texas Health Science CenterSan AntonioUSA
  3. 3.University of CaliforniaSan FranciscoUSA
  4. 4.University of PittsburghPittsburghUSA
  5. 5.Dana Farber Cancer InstituteBostonUSA
  6. 6.University of WisconsinMadisonUSA
  7. 7.University of CaliforniaLos AngelisUSA
  8. 8.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations